Zymeworks Q2 Loss Widens to $45M, but $250M PDUFA Milestone and Theravance Deal Loom
ZYME has more than doubled off its 52-week low of $11.51.
Summary
Zymeworks reported a $45M Q2 loss but highlighted a strong cash position and multiple near-term catalysts, including a $250M PDUFA milestone and the Theravance acquisition. The company is transitioning to a diversified revenue base and will no longer provide cash runway guidance.
Key Events · Earnings and Guidance · ZYME
-
Q2 Net Loss of $45M
Revenue fell to $4.6M from $48.7M a year ago, driven by the absence of non-recurring collaboration milestones. R&D expenses declined 20% to $27.4M, while G&A rose to $19.3M on higher stock-based compensation.
-
$322.5M Cash Position
Cash, equivalents, and marketable securities totaled $322.5M as of June 30, 2026. The company no longer provides cash runway guidance, citing expected recurring cash flows from the Theravance acquisition and zanidatamab milestones.
-
Zanidatamab PDUFA August 25, 2026
The FDA target action date for zanidatamab in first-line HER2+ GEA could trigger a $250M U.S. approval milestone, with up to $190M in additional global regulatory milestones.
-
Theravance Acquisition Closing 2H 2026
The $929M deal is expected to close in the second half of 2026, adding YUPELRI profit share (~$60M annualized cash flow) and other assets. Financing includes a $350M non-recourse note secured by YUPELRI profit share.
Analysis · ZYME · Life Sciences
A $45 million net loss hit the books as collaboration revenue evaporated, yet the balance sheet holds firm with $322.5 million in cash. What matters more are the catalysts ahead: an August 25 PDUFA date for zanidatamab could unlock a $250 million milestone, and the Theravance acquisition—expected to close in the second half of 2026—promises durable commercial cash flows. Early data for the ZW191 ADC also impressed, and management is exploring a separate entity for its Pan-RAS platform. With the Theravance deal on the horizon, the company is dropping cash runway guidance, signaling a shift to a revenue-generating business model.
At the time of this filing, ZYME was trading at $23.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.51 to $29.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.